Sagaliam Acquisition Corp.
SAGAR
NASDAQ Global Market0.04
USD
+0.00
- -
CIK
0001855351
CUSIP
78661R114
Return %
Stock
S&P500
1Y
-65.42
26.53
3Y
-79.41
76.60
5Y
-79.41
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Barry J. Kostiner
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 1800 Avenue of the Stars Los Angeles CA United States of America 90067
- CIK
- 0001855351
- Similar Companies
- Business
- Sagaliam Acquisition Corp is a special purpose acquisition company (SPAC) primarily focused on effecting mergers, acquisitions, and strategic capital exchanges in the biotech and pharmaceutical sectors. The company targets businesses with promising assets in innovative therapeutics, nutraceutical products, and intellectual property related to healthcare solutions. Sagaliam Acquisition Corp leverages a robust acquisition and value creation framework to identify and acquire companies that offer advanced therapeutic solutions and consumer health products. Its core product offerings include proprietary nutraceutical formulations and patented intellectual property in the pharmaceutical space. The company conducts operations primarily within the United States and seeks to expand its portfolio through strategic partnerships and acquisitions. Recent major developments include the launch of an improved IPF (Idiopathic Pulmonary Fibrosis) formula enhanced with Vitamin C available in pill and lozenge forms, as well as the addition of a new slimming nutraceutical product. The company also executed a novation agreement retaining full ownership of VIRO, a significant asset line encompassing ITV-1 and other nutraceutical licenses. In 2024, Sagaliam Acquisition Corp experienced Nasdaq delisting and transitioned to OTC markets while continuing efforts to complete a business combination. The company recently announced the execution of a definitive business combination agreement, confirming funding and extending deadlines for completion. These moves reflect a strategic shift to strengthen its position within the biotech and pharmaceutical acquisition landscape. Founded in 2021 and headquartered in Delaware, Sagaliam Acquisition Corp operates as a blank check entity with a long-term strategic focus on healthcare and biotechnology sectors marked by rapid innovation and critical medical needs. The company emphasizes its expertise in sourcing acquisition targets through proprietary channels and industry relationships, differentiating itself in the competitive SPAC market. Its business model revolves around identifying, acquiring, and enhancing companies that contribute to scalable healthcare solutions and regulatory compliance within its segments. Sagaliam Acquisition Corp’s activities involve collaborating with specialized subsidiaries and partners in developing and commercializing therapeutic and nutraceutical products, aiming at markets that demand scientific innovation and operational precision. Recent strategic alliances include partnerships with companies like Enzolytics, Inc. which support its expansion and product development initiatives. Through these actions, Sagaliam Acquisition Corp continues to position itself as a significant player in biotech acquisitions and clinical-stage healthcare innovation.